- Scrip
Permanent Indian Bar Against Glenmark’s Sitagliptin Copies
An Indian court has permanently enjoined Glenmark from making and selling its generic version of Merck’s diabetes therapies Januvia and Janumet after the Indian firm was found to have infringed the sitagliptin patent.
Glenmark Pharmaceuticals Ltd. cannot sell its versions of Merck & Co. Inc.‘s Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride) in India after a ruling by the Delhi High Court.
Indian Justice A K Pathak, in an 133-page order dated Oct
